Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Boomskidon Jun 08, 2023 11:51pm
201 Views
Post# 35487830

Protalix

ProtalixIf Protalix is about to make an announcement that they have started or are going to start a Fabry/BBB program, then it is likely that this is known by Bioasis, and that they may have known it for some time. If this type of announcement comes, then there may very well be a developmental milestone payment to Bioasis triggered.

Further, if the development of an xB3/Fabry drug (xB3-Elfabrio) was dependent on FDA approval, then Bioasis would have known that for a long time, including during the time that the Midatech deal was being secretly set up.

And yet, if they did know this stuff, Bioasis went ahead with that awful Midatech deal with a timeliness that prevented Bioasis shareholders from knowing that this Fabry thing could happen.

The fact that we are now into June without the loss of xB3 to Lind may mean that Bioasis has received, or is about to receive, a milestone payment from Chiesi. (FDA approval of Elfabrio triggered a $20 million milestone payment by Chiesi to Protalix.)

It won't surprise me if Rathjen "saves" Bioasis with such an eventuality. 

The June 27 Protalix event is a day or two before we would expect to see the Bioasis annual report. Rathjen likes timing these things in ways that suit her disclosure practices.

These things could be good but they still stink.

jd
<< Previous
Bullboard Posts
Next >>